Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14672027 | 0.84 | ALDH1A1 (0.46) | MAPTKDM4EALDH1A1HSD17B10MEN1 | |
| SCHEMBL14672047 | 0.82 | KDM4E (0.44) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL15202860 | 0.81 | HTR1A (0.36) | — | |
| SCHEMBL15505745 | 0.80 | ALDH1A1 (0.43) | MAPTKDM4EALDH1A1HSD17B10MEN1 | |
| SCHEMBL13591192 | 0.78 | MAPT (0.38) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL12125000 | 0.76 | MAPT (0.46) | MAPTKDM4EALDH1A1HSD17B10NPC1 | |
| SCHEMBL4139724 | 0.76 | CRHR1 (0.40) | MAPTKDM4EALDH1A1CRHR1MAPK1 | |
| SCHEMBL14672048 | 0.76 | KDM4E (0.36) | MAPTKDM4EALDH1A1HSD17B10MEN1 | |
| SCHEMBL28202495 | 0.70 | KDM4E (0.47) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL12659714 | 0.70 | MAPT (0.41) | MAPTKDM4EALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981095-B2 | Intermediate compounds and process for the preparation of lurasidone and salts thereof | MAPI PHARMA LTD. (IL) | 2015-03-17 | — | — | US | disclosed |
| US-20140179922-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | MAPI PHARMA LTD. (IL) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179922-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | REN, AVPR1B, AVPR2 | MAPT 608/4885KDM4E 3834/4885ALDH1A1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.